Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

Figure 1

Immunophenotypic characterization of peripheral blood lymphocytes. Percentages of (a) natural killer cells (NK; CD3-CD16+CD56+; neg = 20, pos = 17, ctrl = 17), (b) B cells (CD3-CD19+; neg = 14, pos = 15, ctrl = 15), (c) T lymphocytes (CD3+CD19-; neg = 20, pos = 17, ctrl = 17), (d) CD4+/CD8+ ratio (CD3+CD4+/CD3+CD8+; neg = 20, pos = 17, ctrl = 17), and (e) regulatory T cells (Treg; CD3+CD4+CD25highCD127lowFoxP3+; neg = 20, pos = 15, ctrl = 17) assessed in HER2- (neg), HER2-overexpressing (pos) patients and age-matched healthy women (ctrl). (f) Differentiation (memory) status of CD3+CD4+ and CD3+CD8+ lymphocytes was investigated through CCR7 and CD45RA expression (neg = 12; pos = 10; ctrl = 10). Statistical analysis was performed with t Student test. *, P<0.05 (refer to text for exact P value). HER-2, human epidermal growth factor receptor-2.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us